A Multinational Trial to Evaluate the Longterm Safety of the Parachute Implant System (PARACHUTEIII)
2017年6月21日 更新者:CardioKinetix, Inc
PARACHUTE III: A Multinational Trial to Evaluate the Longterm Safety of the Parachute System
The primary objective is to assess the longterm safety of the CardioKinetix Parachute Implant and Delivery System in the partitioning of the left ventricle in patients with heart failure due to ischemic heart disease.
研究概览
详细说明
While current therapies for heart failure (including but not limited to: medical management, cardiac resynchronization and ICDs) may represent the best treatment available today for the majority of HF patients, the medical community recognizes that pharmacologic therapy has been optimized to nearly the extent that is possible, and that any incremental improvements in the management of HF patients will now come from device based therapies.
With this background, CardioKinetix has developed a catheter-based intravascular approach to ventricular partitioning using an implantable device.
The purpose of this study is to assess the longterm safety of using the CardioKinetix Parachute device to isolate the malfunctioning portion of the left ventricle in patients with symptoms of HF due to ischemic heart disease.
研究类型
观察性的
注册 (实际的)
54
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Bad Nauheim、德国、61231
- Kerckhoff-Klinik SGmbh
-
Bonn、德国、53115
- Arzt St. Marien-Hospital Abt. Innere Medizin
-
Hamburg、德国、20099
- Asklepios Klinik St. Georg
-
Heidelberg、德国、69120
- University of Heidelberg
-
Leipzig、德国、04289
- University Hospital Leipzig
-
Rostock、德国、18057
- Universitat Rostok
-
-
-
-
-
Catania、意大利、95123
- Ferrarotto University Hospital Catania
-
-
-
-
-
Aalst、比利时、9300
- OLV Hospital Aalst
-
Antwerpen、比利时、2020
- ZNA Middelheim
-
-
-
-
-
Glasgow、英国、G81 4DY
- Golden Jubilee Hospital
-
London、英国、SE1 7EH
- St. Thomas' Hospital
-
-
-
-
-
Utrecht、荷兰、3508
- University Medical Center (UMC) Utrecht
-
-
-
-
-
Barcelona、西班牙、08028
- Hospital Clínico de Barcelona
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 79年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
非概率样本
研究人群
The study population will be open to all individuals who meet the inclusion/exclusion criteria.
This is a prospective, multi-center, non-randomized trial.
描述
Inclusion Criteria:
Candidates for this study must meet ALL of the following inclusion criteria:
- Akinesis or dyskinesis due to myocardial infarction limited to anteroapical region
- Subject is not hospitalized at time of enrollment.
NYHA Class at time of enrollment, either:
- NYHA Class III or Ambulatory IV - if predominant during the 3-month period prior to enrollment
- NYHA Class II - if diagnosed with NYHA Class III or IV during 3-month period prior to enrollment
- LVEF >15 or% and ≤ 40% as measured by echocardiography.
- Post LV MI structural heart dysfunction represented by LV wall motion abnormality (WMA) by echocardiography.
- Eligible for cardiac surgery
- Between 18 and 79 years of age (inclusive)
- Receiving appropriate medical treatment for heart failure according to the ACC/AHA 2009 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult during the three months prior to enrollment
- Provide written informed consent
- Agree to the protocol-required follow-up
Exclusion Criteria:
Candidates will be excluded from the study if ANY of the following conditions apply:
- Untreated clinically significant coronary artery disease requiring intervention.
- Acute MI (see MI definition) within 60 days of enrollment or patients with suspected evolving MI at time of enrollment
- Cardiogenic shock within 72 hours of enrollment
- Revascularization procedure (PCI or CABG) within 60 days of enrollment
- Patient has received a pacemaker, ICD, or CRT device within 60 days of enrollment
- History of aborted sudden cardiac death, if patient has not received an ICD and has potentially lethal ventricular arrhythmia, VT or VF
- A known hypersensitivity or contraindication to aspirin, heparin, warfarin, nitinol (titanium and nickel alloy), or sensitivity to contrast media, which cannot be adequately pre medicated.
- Aortic valve replacement or repair
- Blood dyscrasia, history of bleeding diathesis or coagulopathy, or hypercoagulable states.
- Active peptic ulcer or GI bleeding within the past 3 months
- Patient has suffered a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months
- History of Kawasaki's disease
- Patient on dialysis or expected to require hemodialysis within 12 months
- Patient has chronic liver disease
- Impaired renal function that places patient at risk of contrast induced renal failure
- Ongoing sepsis, including active endocarditis.
- Co-morbidities associated with a life expectancy of less than 12-months or there are factors making echo and clinical follow-up difficult (no permanent address, etc.)
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Assessment of long term safety of the Parachute system
大体时间:5 years
|
Assessment of long term safety as measured by site-reported device related MACE in real in real-world use of the Parachute Implant through 5 years of clinical follow-up.
|
5 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Left Ventricular Volume Indices
大体时间:6 months and annually to 5 years
|
Change in Left Ventricular Volume Indexes (End Systolic {LVESVI} and End Diastolic {LVEDVI}) as measured by echocardiography from baseline to 6 months and annually to 5 years
|
6 months and annually to 5 years
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Simon Redwood, MD、St. Thomas' Hospital
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2011年7月1日
初级完成 (实际的)
2014年6月1日
研究完成 (实际的)
2017年6月1日
研究注册日期
首次提交
2011年2月15日
首先提交符合 QC 标准的
2011年2月15日
首次发布 (估计)
2011年2月16日
研究记录更新
最后更新发布 (实际的)
2017年6月22日
上次提交的符合 QC 标准的更新
2017年6月21日
最后验证
2017年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.